Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs
Authors
Keywords
-
Journal
American Journal of Rhinology & Allergy
Volume 27, Issue 3, Pages 206-212
Publisher
SAGE Publications
Online
2013-05-28
DOI
10.2500/ajra.2013.27.3875
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subcutaneous and Sublingual Immunotherapy for Allergic Rhinitis: What is the Evidence?
- (2012) Sarah K. Wise et al. American Journal of Rhinology & Allergy
- Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study
- (2011) L. Klimek et al. CLINICAL AND EXPERIMENTAL ALLERGY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- Mechanisms of allergen-specific immunotherapy
- (2011) Cezmi A. Akdis et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Allergic rhinitis: Direct and indirect costs
- (2010) Michael S. Blaiss ALLERGY AND ASTHMA PROCEEDINGS
- Efficacy and Safety of a Glutaraldehyde-Modified House Dust Mite Extract in Allergic Rhinitis
- (2010) Herbert Riechelmann et al. American Journal of Rhinology & Allergy
- Designing CD8+ T cell vaccines: it's not rocket science (yet)
- (2010) Jonathan W Yewdell CURRENT OPINION IN IMMUNOLOGY
- TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors
- (2010) Sudhanshu Agrawal et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Cutting Edge: Type I IFN Reverses Human Th2 Commitment and Stability by Suppressing GATA3
- (2010) J. P. Huber et al. JOURNAL OF IMMUNOLOGY
- Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients
- (2010) Daniel E. Speiser et al. JOURNAL OF IMMUNOTHERAPY
- Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
- (2009) Jörg Vollmer et al. ADVANCED DRUG DELIVERY REVIEWS
- BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation
- (2009) J. Eckl-Dorna et al. BLOOD
- Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
- (2009) G. Senti et al. CLINICAL AND EXPERIMENTAL ALLERGY
- TLR Cross-Talk Specifically Regulates Cytokine Production by B Cells from Chronic Inflammatory Disease Patients
- (2009) M. Jagannathan et al. JOURNAL OF IMMUNOLOGY
- Mechanism of action of licensed vaccine adjuvants
- (2009) Elaine Tritto et al. VACCINE
- Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells
- (2009) Eric F. Tewalt et al. PLoS Pathogens
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
- (2008) J. Bousquet et al. ALLERGY
- The coming of age of virus-like particle vaccines
- (2008) Gary T. Jennings et al. BIOLOGICAL CHEMISTRY
- Nanoparticles target distinct dendritic cell populations according to their size
- (2008) Vania Manolova et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
- Allergen-related approaches to immunotherapy
- (2008) Jennifer M. Rolland et al. PHARMACOLOGY & THERAPEUTICS
- Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
- (2008) G. Senti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started